Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
PTPN14
REST API REST API
Homo sapiens
PTPN14 is differentially expressed in 248 experiments: 138 organism parts: liver, placenta, ... (136 more);, 189 disease states: normal, acute lymphoblastic leukemia, ... (187 more);, 79 cell types 349 cell lines 29 compound treatments and 69 other conditions.
Synonyms PEZ
Orthologs PTPN14 (Bos taurus)   Ptpn14 (Mus musculus)   PTP1 (Saccharomyces cerevisiae)   PTPN14 (Gallus gallus)   Ptpn14 (Rattus norvegicus)   Pez (Drosophila melanogaster)   ptpn14 (Xenopus laevis)   PTPN14 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term phosphatase activity, cytoskeleton, cytoplasm, dephosphorylation, protein tyrosine/serine/threonine phosphatase activity, protein tyrosine phosphatase activity, receptor activity, hydrolase activity, binding, lymphangiogenesis, receptor tyrosine kinase binding, peptidyl-tyrosine dephosphorylation, protein dephosphorylation
InterPro Term Tyr_Pase_cat, FERM_central, Band_41_domain, Dual-sp_phosphatase_cat-dom, Tyr_Pase_rcpt/non-rcpt, FERM_domain, Tyr_Pase_non-rcpt_typ-14/21, Band_41_fam, FERM_N, FERM_PH-like_C, Tyr/Dual-specificity_Pase
UniProt Accession Q15678, E2J9M0
Gene-Disease Assocation CHOANAL ATRESIA AND LYMPHEDEMA
Search EB-eye ENSG00000152104
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, ... (26 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-19397, ... (34 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-19639, E-GEOD-20081, E-GEOD-3529
A549
2
E-GEOD-3202, E-GEOD-6013
HT1080
2
E-MTAB-37, E-GEOD-20089
LNCaP
2
E-GEOD-14990, E-GEOD-14464
MCF-10A
2
E-GEOD-14990, E-TABM-420
MOLT4
2
E-MTAB-62, E-MTAB-37
343 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-MEXP-750, E-MEXP-66, E-GEOD-4219, ... (38 experiments)

Factor Value U/D Experiments
germ cell
1
E-MTAB-25
induced pluripotent stem cell
1
E-GEOD-18265
BDCA4+ dentritic cell
1
E-TABM-145
spheroid
1
E-GEOD-4219
Monocytes
1
E-GEOD-21909
astrocyte
1
E-GEOD-4483
73 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-1615, E-GEOD-15960, E-GEOD-2466, E-MEXP-2069, ... (45 experiments)

Factor Value U/D Experiments
dermatomyositis
2
E-GEOD-5370, E-MTAB-62
control
2
E-GEOD-16363, E-GEOD-8121
acute promyelocytic leukemia
2
E-MTAB-62, E-GEOD-995
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
breast cancer
2
E-MTAB-62, E-GEOD-22544
choriocarcinoma
2
E-MTAB-62, E-MTAB-37
183 more value(s).


Compound treatment

studied in E-GEOD-6907, E-GEOD-5741, E-TABM-782, E-GEOD-5824, E-GEOD-5099, ... (22 experiments)

Factor Value U/D Experiments
none
2
6
E-GEOD-412, E-GEOD-2649, E-GEOD-5824, E-GEOD-20719, E-GEOD-2803, ... (8 experiments)
lipopolysaccharide
1
E-MEXP-1958
LDL
1
1
E-GEOD-5741
resveratrol
1
E-TABM-782
filtered air
1
E-TABM-127
CNOT7+CNOT8
1
1
E-MEXP-2218
23 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-21374, E-GEOD-21589, ... (7 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-GEOD-6236, ... (9 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-3325, E-TABM-147, E-GEOD-21138, ... (6 experiments)

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, ... (6 experiments)

Genotype
studied in E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, E-TABM-868, E-GEOD-18005, ... (13 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-2657, E-GEOD-12773, E-GEOD-21612, E-TABM-127, E-GEOD-20540, ... (11 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-1926, E-TABM-666, E-MEXP-1648, ... (23 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-MEXP-561

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-22056

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, E-GEOD-17636 ... (5 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-3254, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Replicate
studied in E-GEOD-19330, E-GEOD-17204

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-MEXP-1509, E-GEOD-3697, E-MEXP-2759

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

Sex
studied in E-GEOD-19069, E-GEOD-2466, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-11428

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-4922, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-13818

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561, E-GEOD-4922

weight of protein recovered
studied in E-GEOD-21918

Processing time: 0.332 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM